Dynamic Amyloid-PET/MRI: Relationships to Flortaucipir Uptake in Alzheimers Disease

Conclusions: Training data suggests that eCBF measures from dynamic florbetapir-PET studies strongly correlate with tau positivity measured with flortaucipir-PET across all subjects irrespective of amyloid status. Successful development of this approach could simplify and decrease the cost of acquiring neuroimaging biomarkers of amyloid and tau. References: Raman F, et al. (2019) Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Methodology for Research and Clinical Brain PET Applications. J Alzheimers Dis 70, 1241-1257. **NOTES: Data used in preparation of this article were obtained from the Charles F. and Joanne Knight Alzheimer’s Disease Research Center (Knight ADRC) at Washington University in St. Louis School of Medicine. A complete listing of Knight ADRC investigators and goals can be found at https://knightadrc.wustl.edu

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Raman, F., Fang, Y.-H., Grandhi, S., Murchison, C., Kennedy, R., Morris, J., Massoumzadeh, P., Benzinger, T., Roberson, E., McConathy, J. Tags: Amyloid & amp; Tau PET Source Type: research